Overview
KEEP ME INFORMED
In a changing and expanding world, this is the only forum designed for QPPVs by QPPVs, now in its 13th year and still going strong.
In 2019 the forum is expanding to a global approach on the topics, programme committee composition and programme content. In addition, its location moves to Amsterdam to be in line with the new EMA office.
This Forum continues to identify key trends requiring QPPV awareness, input and oversight. This year’s objectives are built on past successes and have been shaped by valuable feedback provided by participants of the past twelve meetings, plus many years of QPPV and Regulator interaction at this Forum. Moreover, we are looking forward to receive information on the globalization of the QPPV role.
Over time, one of the key successes of the Forum has been the ability to secure the continuing support and involvement of key regulators. Sessions have been open and interactive with attendees appreciating opportunities to raise challenging issues in an informal environment. The 13th QPPV Forum continues this successful approach.
Program Committee
-
Peter De Veene, MD GQPPV
MSD Belgium, Belgium -
Elspeth McIntosh, MBA, RN Director
Castle Pharmacovigilance Ltd, United Kingdom -
Vicki Edwards, RPh Vice President, Pharmacovigilance Excellence and International QPPV
Abbvie, United Kingdom -
Mette Stockner, MD Senior Pharmacovigilance Director
Savara ApS, Denmark -
Doris Irene Stenver, MD, MPA Independent Pharmacovigilance Adviser
Unique Advice, Denmark -
Shahinaz Badr Pharmacovigilance Consultant and PVQA Auditor - EMEA
Pharma Quality Europe, United Arab Emirates -
Magnus Ysander, MD EU & UK QPPV & Head Pharmacovigilance Excellence
AstraZeneca, Sweden -
Nicolas Tsiakkas, MD Scientific Director
NIKOLAS TSIAKKAS AND CO OE, Greece -
Willemijn van der Spuij, MSc Executive Director, WorldWide Patient Safety International, Europe
Switzerland -
Angela Van Der Salm, PhD, MSc Director PV, Managing partner
DADA Consultancy B.V., Netherlands -
Gemma Jimenez Sese Senior Director, Deputy EU QPPV
AstraZeneca, Spain -
Katarzyna Swiderek, MPharm, RPh Director, Safety Evaluation Risk Management (SERM)
GlaxoSmithKline, Poland
Have an account?